The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Open accessAbstract
BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paxlovid was shown to be highly effective at preventing progression to severe COVID-19 in symptomatic patients105.”
From Advances in covalent drug discovery (2022) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,002
Early combination therapy of COVID-19 in high-risk patients
Orth, H. M., Flasshove, C., Berger, M., Hattenhauer, T., Biederbick, K., Mispelbaum, R., Klein, U. K. A., Stemler, J., Fisahn, M., Doleschall, A., et al. (2023) · Infection · doi:10.1007/s15010-023-02125-5 · Cited by 40
Yin, X., Zhu, W., Tang, X., Yang, G., Zhao, X., Zhao, K., Jiang, L., Li, X., Zhao, H., Wang, X., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12228-3 · Cited by 41
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Gupta, Y. A., Savytskyi, O. V., Coban, M., Venugopal, A., Pleqi, V., Weber, C. A., Chitale, R. A., Durvasula, R. V., Hopkins, C. E., Kempaiah, P., et al. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101151 · Cited by 40
Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis
Barnette, K. G., Gordon, M. S., Rodriguez, D., Bird, T. G., Skolnick, A., Schnaus, M. J., Skarda, P. K., Lobo, S. M., Sprinz, E., Arabadzhiev, G., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200145 · Cited by 39
Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
Wong, G. L., Yip, T. C., Lai, M. S., Wong, V. W., Hui, D. S. C., & Lui, G. C.-Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45086 · Cited by 39
Mazzitelli, M., Mengato, D., Sasset, L., Ferrari, A. M., Gardin, S., Scaglione, V., Bonadiman, N., Calandrino, L., Cavinato, S., Trivellato, S., et al. (2023) · Viruses · doi:10.3390/v15020384 · Cited by 39
Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
Ross, S. B., Bortolussi‐Courval, É., Hanula, R., Lee, T. C., Wilson, M. G., & McDonald, E. G. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20184 · Cited by 39
Outcome of early treatment of SARS‐CoV ‐2 infection in patients with haematological disorders
Mikulska, M., Testi, D., Russo, C., Balletto, E., Sepulcri, C., Bussini, L., Dentone, C., Magnè, F., Policarpo, S. N., Campoli, C., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18690 · Cited by 39
Lui, D. T. W., Chung, M. S. H., Lau, E. H. Y., Lau, K. T. K., Au, I. C. H., Lee, C., Woo, Y. C., Wong, C. K. H., & Cowling, B. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14393 · Cited by 38
Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
Fung, K. W., Baye, F. M., Baik, S. H., & McDonald, C. J. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.5099 · Cited by 38
Choi, M. H., Wan, E. Y. F., Wong, I. C. K., Chan, E. W., Chu, W. M., Tam, A. R., Yuen, K. Y., & Hung, I. F. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00353-0 · Cited by 38
Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic
Flaherty, G. T., Hamer, D. H., & Chen, L. H. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00784-3 · Cited by 38
Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection
Chen, W., Liang, B., Wu, X., Li, L., Wang, C., & Xing, D. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.10.005 · Cited by 38
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
Παπαδοπούλου, Α., Karavalakis, G., Papadopoulou, E., Xochelli, A., Bousiou, Z., Vogiatzoglou, A., Papayanni, P. G., Georgakopoulou, A., Giannaki, M., Stavridou, F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02480-8 · Cited by 39
Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations
Xu, J.-Q., Zhang, W.-Y., Fu, J.-J., Fang, X.-Z., Gao, C.-G., Li, C., Yao, L., Li, Q.-L., Yang, X.-B., Ren, L.-H., et al. (2024) · Military Medical Research · doi:10.1186/s40779-024-00581-0 · Cited by 37
Shah, M. M., Joyce, B., Plumb, I. D., Sahakian, S., Feldstein, L. R., Barkley, E., Paccione, M., Deckert, J., Sandmann, D., Gerhart, J. L., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.12.004 · Cited by 37
Yang, H., Wang, Z., Jiang, C., Zhang, Y., Zhang, Y., Xu, M., Zhang, Y., Wang, Y., Liu, X., An, Z., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28947 · Cited by 37
Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023
Solera, J. T., Árbol, B. G., Mittal, A., Hall, V. G., Marinelli, T. M., Bahinskaya, I., Selzner, N., McDonald, M. A., Schiff, J. R., Sidhu, A., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.03.011 · Cited by 37
A coronavirus assembly inhibitor that targets the viral membrane protein
Laporte, M., Jochmans, D., Bardiot, D., Desmarets, L. M. B., Debski-Antoniak, O. J., Mizzon, G., Abdelnabi, R., Leyssen, P., Chiu, W., Zhang, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-08773-x · Cited by 37
Tian, F., Chen, Z., & Feng, Q. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28732 · Cited by 37
Salmanton‐García, J., Marchesi, F., da Silva, M. G., Farina, F., Dávila, J., Bilgin, Y. M., Glenthøj, A. B., Falces‐Romero, I., van Doesum, J. A., Labrador, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101939 · Cited by 36
Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses
Owens, K. L., Esmaeili, S., & Schiffer, J. T. (2024) · JCI Insight · doi:10.1172/jci.insight.176286 · Cited by 40
Innate Immunity in Protection and Pathogenesis During Coronavirus Infections and COVID-19
Malireddi, R. K. S., Sharma, B. R., & Kanneganti, T. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043545 · Cited by 39
Rhodin, M. H. J., Reyes, A. C., Balakrishnan, A., Bisht, N., Kelly, N., Gibbons, J. S., Lloyd, J., Vaine, M., Cressey, T. N., Crepeau, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50931-8 · Cited by 36
Tuttle, J. B., Allais, C., Allerton, C. M. N., Anderson, A. S., Arcari, J. T., Aschenbrenner, L. M., Avery, M., Bellenger, J., Berritt, S., Boras, B. W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02561 · Cited by 36
Gu, Y., Li, A., Zeng, Y., He, M., Qi, F., Liu, R., Cai, H., Li, D., Tang, X., Fu, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv6990 · Cited by 37
Lowe, D. M., Brown, L. K., Chowdhury, K., Davey, S., Yee, P., Ikeji, F., Ndoutoumou, A., Shah, D., Lennon, A., Rai, A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004120 · Cited by 38
Loos, N. H. C., Beijnen, J. H., & Schinkel, A. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114636 · Cited by 36
Dioverti, M. V., Boghdadly, Z. E., Shahid, Z., Waghmare, A., Abidi, M. Z., Pergam, S. A., Boeckh, M., Dadwal, S., Kamboj, M., Seo, S. K., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.09.002 · Cited by 35
Razonable, R. R., O’Horo, J. C., Hanson, S. N., Arndt, R. F., Speicher, L. L., Seville, T. A., Hall, S. T., Pike, M. L., Heyliger, A., Larsen, J. J., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac346 · Cited by 36
Гудима, Г. О., Кофиади, И. А., Shilovskiy, I. P., Kudlay, D. A., & Khaitov, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108867 · Cited by 37
Esmaeili, S., Owens, K. L., Wagoner, J., Polyak, S. J., White, J. M., & Schiffer, J. T. (2024) · Nature Communications · doi:10.1038/s41467-024-49458-9 · Cited by 35
Weng, C., Xie, R., Han, G., Yuan, Y., Li, S., Wang, C., Wang, X., Jiang, W., & Jiang, L. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00760-x · Cited by 35
Lingscheid, T., Kinzig, M., Krüger, A., Müller, N. B., Bölke, G., Tober‐Lau, P., Münn, F., Kriedemann, H., Witzenrath, M., Sander, L. E., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01229-22 · Cited by 34
Baldi, F., Dentone, C., Mikulska, M., Fenoglio, D., Mirabella, M., Magnè, F., Portunato, F., Altosole, T., Sepulcri, C., Giacobbe, D. R., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1062450 · Cited by 34
Wang, F., Xiao, W., Tang, Y., Cao, M., Shu, D., Asakawa, T., Xu, Y., Jiang, X., Zhang, L., Wang, W., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100835 · Cited by 34
Cox, R. M., Lieber, C. M., Wolf, J. D., Karimi, A., Lieberman, N. A. P., Sticher, Z. M., Roychoudhury, P., Andrews, M. K., Krueger, R. E., Natchus, M. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40556-8 · Cited by 34
Alternative splicing in lung influences COVID-19 severity and respiratory diseases
Nakanishi, T., Willett, J., Farjoun, Y., Allen, R. J., Guillén‐Guío, B., Adra, D., Zhou, S., & Richards, J. B. (2023) · Nature Communications · doi:10.1038/s41467-023-41912-4 · Cited by 35
Sullivan, D. J., Focosi, D., Hanley, D. F., Cruciani, M., Franchini, M., Ou, J., Casadevall, A., & Paneth, N. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29310 · Cited by 35
Fernández‐de‐las‐Peñas, C., Torres‐Macho, J., Catahay, J. A., Macasaet, R., Velasco, J. V., Macapagal, S. C., Caldararo, M. D., Henry, B. M., Lippi, G., Franco‐Moreno, A., et al. (2023) · Infection · doi:10.1007/s15010-023-02154-0 · Cited by 34
Elias, K. M., Khan, S. R., Stadler, E., Schlub, T. E., Cromer, D., Polizzotto, M. N., Kent, S. J., Turner, T., Davenport, M. P., & Khoury, D. S. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00398-1 · Cited by 35
Wang, X., Xiong, L., Zhu, Y., Liu, S., Zhao, W., Wu, X., Seydimemet, M., Li, L., Ding, P., Lin, X., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c12992 · Cited by 34
First-generation oral antivirals against SARS-CoV-2
Sendi, P., Razonable, R. R., Nelson, S. B., Soriano, À., & Gandhi, R. T. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.04.015 · Cited by 34
Yan, G., Zhou, J., Zhu, H., Chen, Y., Lu, Y., Zhang, T., Yu, H., Wang, L., Xu, H. M., Wang, Z., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2791 · Cited by 34
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside
Laracy, J. C., Kamboj, M., & Vardhana, S. A. (2022) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000841 · Cited by 34
Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
Mali, K. R., Eerike, M., Raj, G. M., Bisoi, D., Priyadarshini, R., Ravi, G., Chaliserry, L. F., & Janti, S. S. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03139-y · Cited by 33
Bonet, D. B., Caguana-Vélez, O. A., Durán, X., Comas, M., Posso, M., Admetlló, M., Blasco, A. H., Cuadrado‐Godia, E., Marco, E., Martín‐Ezquerra, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124158 · Cited by 35
Meier, A., Sakoulas, G., Nizet, V., & Ulloa, E. R. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae252 · Cited by 37
An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models
Leekha, A., Saeedi, A., Kumar, M., Sefat, K. M. S. R., Martinez-Paniagua, M. A., Meng, H., Fathi, M., Kulkarni, R. S., Reichel, K., Biswas, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50234-y · Cited by 33
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )
Yang, Y., Luo, Y., Zhang, C., Xiang, Y., Bai, X., Zhang, D., Fu, Z., Hao, R.-B., & Liu, X. (2024) · ACS Omega · doi:10.1021/acsomega.4c03023 · Cited by 34
Bhatia, A., Preiss, A., Xiao, X., Brannock, D., Alexander, G. C., Chew, R., Davis, H., Fitzgerald, M., Hill, E., Kelly, E., et al. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004493 · Cited by 33
Singh, R. S. P., Walker, G. S., Kadar, E. P., Cox, L. M., Eng, H. F., Sharma, R., Bergman, A. J., Eyck, L. V., Hackman, F., Toussi, S. S., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2683 · Cited by 33
Li, H., Gao, M., You, H., Zhang, P., Pan, Y., Li, N., Qin, L., Wang, H., Li, D., Li, Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac600 · Cited by 33
Structural and functional characterization of NEMO cleavage by SARS-CoV-2 3CLpro
Hameedi, M. A., Prates, E. T., Garvin, M. R., Mathews, I. I., Amos, B. K., Demerdash, O., Bechthold, M., Iyer, M., Rahighi, S., Kneller, D. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32922-9 · Cited by 34
Green, A. C. A., Curtis, H. J., Higgins, R., Nab, L., Mahalingasivam, V., Smith, R. M., Mehrkar, A., Inglesby, P., Drysdale, H., DeVito, N., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000276 · Cited by 33
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors
Tan, B., Sacco, M. D., Tan, H., Li, K., Joyce, R., Zhang, X., Chen, Y., & Wang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115667 · Cited by 33
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
Congdon, S., Narrowe, Z., Yone, N., Gunn, J., Deng, Y., Nori, P., Cowman, K., Islam, M., Rikin, S., & Starrels, J. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-46912-4 · Cited by 33
Smith-Jeffcoat, S. E., Deyoe, J. E., Talbot, H. K., Morrissey, K. G., Stockwell, M. S., Maldonado, Y., McLean, H. Q., Ellingson, K., Bowman, N. M., Asturias, E. J., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad696 · Cited by 33
Martinez, D. R., Moreira, F. R., Catanzaro, N., Diefenbacher, M. V., Zweigart, M. R., Gully, K. L., la Cruz, G. D., Brown, A. J., Adams, L. E., Yount, B. L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj4504 · Cited by 35
An explanation for SARS-CoV-2 rebound after Paxlovid treatmentPreprint
Perelson, A. S., Ribeiro, R. M., & Phan, T. (2023) · medRxiv · doi:10.1101/2023.05.30.23290747 · Cited by 33
Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
VITO, A. D., Colpani, A., Bitti, A., Zauli, B., Meloni, M. C., Fois, M., Denti, L., Bacciu, S., Marcia, C., Maida, I. R., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28011 · Cited by 32
Evering, T. H., Chew, K. W., Giganti, M. J., Moser, C., Pinilla, M., Wohl, D. A., Currier, J. S., Eron, J. J., Javan, A. C., Ignacio, R. B., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3428 · Cited by 32
Flisiak, R., Horban, A., Jaroszewicz, J., Kozielewicz, D., Mastalerz–Migas, A., Owczuk, R., Parczewski, M., Pawłowska, M., Piekarska, A., Simon, K. A., et al. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16230 · Cited by 34
Chen, K., Krischuns, T., Varga, L. O., Harigua‐Souiai, E., Paisant, S., Zettor, A., Chiaravalli, J., Delpal, A., Courtney, D., O’Brien, A., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105272 · Cited by 32
Watson, J. A., Kissler, S. M., Day, N., Grad, Y. H., & White, N. J. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00192-22 · Cited by 33
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Smith, D. J., Lambrou, A. S., & Patel, P. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7251a1 · Cited by 33
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Reis, S., Metzendorf, M., Kuehn, R., Popp, M., Gágyor, I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015395.pub3 · Cited by 31
Yao, L., Guo, W., Wang, Z., Xiang, S., Liu, W., & Ke, G. (2024) · JACS Au · doi:10.1021/jacsau.3c00737 · Cited by 36
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity
Yang, M., Li, C., Ye, G., Shen, C., Shi, H., Zhong, L., Tian, Y., Zhao, M., Wu, P., Hussain, A., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01748-w · Cited by 31
Mazzotta, V., Cozzi‐Lepri, A., Colavita, F., Rosati, S., Lalle, E., Cimaglia, C., Paulicelli, J., Mastrorosa, I., Vita, S., Fabeni, L., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28186 · Cited by 32
Wang, Y., Zhao, D., Liu, X., Chen, X., Xiao, W., & Feng, L. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28443 · Cited by 31
Now is the time to fix the evidence generation system
Califf, R. M. (2023) · Clinical Trials · doi:10.1177/17407745221147689 · Cited by 31
Chuang, M., Wu, J., Liu, T., Hsu, W., Tsai, Y., Huang, P., & Lai, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28750 · Cited by 31
Ou, J., Lewandowski, E. M., Hu, Y., Lipinski, A. A., Aljasser, A. A., Colon-Ascanio, M., Morgan, R. T., Jacobs, L. M. C., Zhang, X., Bikowitz, M. J., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011592 · Cited by 31
Luvira, V., Schilling, W. H., Jittamala, P., Watson, J. A., Boyd, S., Siripoon, T., Ngamprasertchai, T., Almeida, P. J., Ekkapongpisit, M., Cruz, C. V., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-023-08835-3 · Cited by 31
SARS-CoV-2 Infection and COVID-19 in Children
Waghmare, A., & Hijano, D. R. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.11.014 · Cited by 32
Xu, J., Song, J., Xie, Z., Yang, J. W., Wu, D., Liu, F., Zhao, Y., Zang, H., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000036714 · Cited by 30
SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations
Soares, V. C., Moreira, I. B. G., & Dias, S. D. S. G. (2025) · Viruses · doi:10.3390/v17081064 · Cited by 33
Brady, D. K., Gurijala, A. R., Huang, L., Hussain, A. A., Lingan, A. L., Pembridge, O. G., Ratangee, B. A., Sealy, T. T., Vallone, K. T., & Clements, T. P. (2022) · FEBS Journal · doi:10.1111/febs.16662 · Cited by 30
Alteri, C., Fox, V., Scutari, R., Burastero, G. J., Volpi, S., Faltoni, M., Fini, V., Granaglia, A., Esperti, S., Gallerani, A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04322-8 · Cited by 30
How to use COVID-19 antiviral drugs in patients with chronic kidney disease
Kale, A., Shelke, V., Dagar, N., Anders, H., & Gaikwad, A. B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1053814 · Cited by 30
Abdelnabi, R., Jochmans, D., Donckers, K., Trüeb, B. S., Ebert, N., Weynand, B., Thiel, V., & Neyts, J. H. (2023) · Nature Communications · doi:10.1038/s41467-023-37773-6 · Cited by 30
Zur, M., Peselev, T., Yanko, S., Rotshild, V., & Matok, I. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105768 · Cited by 30
DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Strine, M. S., Cai, W. L., Wei, J., Alfajaro, M. M., Filler, R. B., Biering, S. B., Sarnik, S. A., Chow, R. D.-W., Patil, A., Cervantes, K. S., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002097 · Cited by 29
Artificial Intelligence in Retrosynthesis Prediction and its Applications in Medicinal Chemistry
Long, L., Li, R., & Zhang, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02749 · Cited by 33
Wearable Sensor-Based Detection of Influenza in Presymptomatic and Asymptomatic Individuals
Temple, D. S., Hegarty‐Craver, M., Furberg, R., Preble, E. A., Bergstrom, E., Gardener, Z., Dayananda, P., Taylor, L., Lemm, N., Papargyris, L., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac262 · Cited by 29
Recent advances in small-molecular therapeutics for COVID-19
Zhong, L., Zhao, Z., Peng, X., Zou, J., & Yang, S. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac024 · Cited by 29
HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment
Basoulis, D., Mastrogianni, E., Voutsinas, P.-M., & Psichοgiou, M. (2023) · Viruses · doi:10.3390/v15020577 · Cited by 29
Ryoo, S., Koh, D.-H., Yu, S., Choi, M., Huh, K., Yeom, J., & Heo, J. Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0272826 · Cited by 30
Mazzotta, V., Cozzi‐Lepri, A., Lanini, S., Mondi, A., Carletti, F., Tavelli, A., Gagliardini, R., Vita, S., Pinnetti, C., Aguglia, C., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28868 · Cited by 29
Wang, H., Wei, Y., Hung, C. T., Lin, G., Jiang, X., Li, C., Jia, K. M., Yam, C. H. K., Chow, T. Y., Ho, J., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00217-2 · Cited by 29
Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid
Wang, Y., Chen, X., Xiao, W., Zhao, D., & Feng, L. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.08.012 · Cited by 29
Gharbharan, A., Jordans, C. C. E., Zwaginga, L., Papageorgiou, G., van Geloven, N., van Wijngaarden, P., den Hollander, J., Karim, F., van Leeuwen-Segarceanu, E., Soetekouw, R., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.08.005 · Cited by 29
Wei, W., Liaw, C., Tsai, K.-C., Chiou, C., Tseng, Y.-H., Chiou, W., Lin, Y., Tsai, C.-I., Lin, C.-S., Lin, C., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106424 · Cited by 28
Zhong, W., Jiang, X., Yang, X., Feng, T., Duan, Z., Wang, W. J., Sun, Z.-L., Chen, L., Nie, X., Zhu, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.980002 · Cited by 30
Ensitrelvir as a potential treatment for COVID-19
McCarthy, M. W. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2146493 · Cited by 28
Coronavirus Disease-2019 in the Immunocompromised Host
Bertini, C. D., Khawaja, F., & Sheshadri, A. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.11.012 · Cited by 30
Early peripheral blood MCEMP1 and HLA-DRA expression predicts COVID-19 prognosis
Chan, K. R., Koh, C. W., Ng, D. H. L., Qin, S., Ooi, J. S. G., Ong, E. Z., Zhang, S. L. X., Sam, H., Kalimuddin, S., Low, J. G. H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104472 · Cited by 28
Breeden, M., Aitken, S. L., Baang, J. H., Gravelin, M., Kaul, D. R., Lauring, A. S., Petty, L. A., & Gregg, K. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad189 · Cited by 28
Tan, R. Y., Wong, B., Lim, R., Lee, C. L., Tan, J. Y. S., Tan, K. B., & Wee, L. E. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100919 · Cited by 28
Metadata
- Authors
- Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
- Affiliations
- Pfizer (United States) (US)
- From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
- Corresponding author
- Hammond, Jennifer
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-04-14
- Volume
- 386
- Issue
- 15
- Pages
- 1397-1408
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8908851
- OpenAlex
- W4212904481
- Cited by
- 2,323
- References
- 21
- Citations by year
- 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
- FWCI
- 261.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
- MeSH terms
- Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
